Cwm LLC Increases Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Cwm LLC significantly increased its holdings in Regeneron Pharmaceuticals by 770.0% in the second quarter, accumulating a total of 35,506 shares valued at approximately $18.64 million.
• Regeneron reported a quarterly earnings per share of $12.89, exceeding analysts' expectations of $8.43, and achieved quarterly revenue of $3.68 billion, which also surpassed estimates.
• The company declared a quarterly dividend of $0.88 per share, representing an annualized payout of $3.52 and a yield of 0.6%.

Cwm LLC raised its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 770.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 35,506 shares of the biopharmaceutical company's stock after buying an additional 31,425 shares during the quarter. Cwm LLC's holdings in Regeneron Pharmaceuticals were worth $18,641,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently modified their holdings of REGN. E Fund Management Hong Kong Co. Ltd. lifted its stake in Regeneron Pharmaceuticals by 344.4% during the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 31 shares during the last quarter. Activest Wealth Management increased its holdings in shares of Regeneron Pharmaceuticals by 110.5% in the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 21 shares during the period. Costello Asset Management INC bought a new stake in Regeneron Pharmaceuticals in the first quarter valued at approximately $27,000. Saudi Central Bank purchased a new stake in Regeneron Pharmaceuticals during the 1st quarter valued at $27,000. Finally, Colonial Trust Advisors purchased a new stake in Regeneron Pharmaceuticals during the 1st quarter valued at $32,000. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Stock Down 0.9%

Shares of REGN stock opened at $564.63 on Monday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $1,024.36. The company has a 50 day simple moving average of $573.95 and a two-hundred day simple moving average of $564.02. The stock has a market cap of $59.85 billion, a P/E ratio of 14.23, a P/E/G ratio of 1.80 and a beta of 0.31. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The firm had revenue of $3.68 billion for the quarter, compared to analysts' expectations of $3.30 billion. During the same period in the previous year, the firm earned $11.56 EPS. The business's quarterly revenue was up 3.6% on a year-over-year basis. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.87%.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on REGN. Royal Bank Of Canada raised their target price on Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a "sector perform" rating in a research note on Monday, August 4th. Sanford C. Bernstein lifted their price target on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an "outperform" rating in a research report on Wednesday, August 27th. Jefferies Financial Group upped their target price on shares of Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a "buy" rating in a research report on Wednesday, August 27th. Redburn Atlantic raised shares of Regeneron Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, August 14th. Finally, Rothschild & Co Redburn began coverage on Regeneron Pharmaceuticals in a research note on Thursday, August 14th. They set a "buy" rating and a $890.00 price objective for the company. Three analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $817.46.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.